181 related articles for article (PubMed ID: 28133920)
1. Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.
Akatsu Y; Yoshimatsu Y; Tomizawa T; Takahashi K; Katsura A; Miyazono K; Watabe T
Cancer Sci; 2017 Jan; 108(1):151-155. PubMed ID: 28133920
[TBL] [Abstract][Full Text] [Related]
2. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.
Cunha SI; Pardali E; Thorikay M; Anderberg C; Hawinkels L; Goumans MJ; Seehra J; Heldin CH; ten Dijke P; Pietras K
J Exp Med; 2010 Jan; 207(1):85-100. PubMed ID: 20065063
[TBL] [Abstract][Full Text] [Related]
3. Activin receptor inhibitors--dalantercept.
Gupta S; Gill D; Pal SK; Agarwal N
Curr Oncol Rep; 2015 Apr; 17(4):14. PubMed ID: 25708802
[TBL] [Abstract][Full Text] [Related]
4. A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity.
Liu L; Yu H; Huang X; Tan H; Li S; Luo Y; Zhang L; Jiang S; Jia H; Xiong Y; Zhang R; Huang Y; Chu CC; Tian W
BMC Cancer; 2015 Mar; 15():170. PubMed ID: 25881012
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
6. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
[TBL] [Abstract][Full Text] [Related]
7. Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.
Hawinkels LJ; de Vinuesa AG; Paauwe M; Kruithof-de Julio M; Wiercinska E; Pardali E; Mezzanotte L; Keereweer S; Braumuller TM; Heijkants RC; Jonkers J; Löwik CW; Goumans MJ; ten Hagen TL; ten Dijke P
Clin Cancer Res; 2016 Jan; 22(1):96-106. PubMed ID: 26373572
[TBL] [Abstract][Full Text] [Related]
8. Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.
Yu DC; Lee JS; Yoo JY; Shin H; Deng H; Wei Y; Yun CO
Mol Ther; 2012 May; 20(5):938-47. PubMed ID: 22273580
[TBL] [Abstract][Full Text] [Related]
9. A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2.
Tseng FJ; Chen YC; Lin YL; Tsai NM; Lee RP; Chung YS; Chen CH; Liu YK; Huang YS; Hwang CH; Lai YK; Liao KW
Cancer Biol Ther; 2010 Nov; 10(9):865-73. PubMed ID: 20818186
[TBL] [Abstract][Full Text] [Related]
10. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.
Scharpfenecker M; van Dinther M; Liu Z; van Bezooijen RL; Zhao Q; Pukac L; Löwik CW; ten Dijke P
J Cell Sci; 2007 Mar; 120(Pt 6):964-72. PubMed ID: 17311849
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.
de Vinuesa AG; Bocci M; Pietras K; Ten Dijke P
Biochem Soc Trans; 2016 Aug; 44(4):1142-9. PubMed ID: 27528762
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
Wang X; Solban N; Khanna P; Callea M; Song J; Alsop DC; Pearsall RS; Atkins MB; Mier JW; Signoretti S; Alimzhanov M; Kumar R; Bhasin MK; Bhatt RS
Oncotarget; 2016 Jul; 7(27):41857-41869. PubMed ID: 27248821
[TBL] [Abstract][Full Text] [Related]
13. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities.
Lee DH; Lee MY; Seo Y; Hong HJ; An HJ; Kang JS; Kim HM
Biomaterials; 2018 Jul; 171():34-45. PubMed ID: 29679794
[TBL] [Abstract][Full Text] [Related]
14. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.
Mitchell D; Pobre EG; Mulivor AW; Grinberg AV; Castonguay R; Monnell TE; Solban N; Ucran JA; Pearsall RS; Underwood KW; Seehra J; Kumar R
Mol Cancer Ther; 2010 Feb; 9(2):379-88. PubMed ID: 20124460
[TBL] [Abstract][Full Text] [Related]
15. BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo.
Suzuki Y; Ohga N; Morishita Y; Hida K; Miyazono K; Watabe T
J Cell Sci; 2010 May; 123(Pt 10):1684-92. PubMed ID: 20406889
[TBL] [Abstract][Full Text] [Related]
16. SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2.
Choi HS; Kim MK; Lee K; Lee KM; Choi YK; Shin YC; Cho SG; Ko SG
Oncotarget; 2016 May; 7(22):32969-79. PubMed ID: 27105528
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
19. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
